Research & Development
Fors Marsh to offer Sera Prognostics preterm birth risk test to employees
The PreTRM blood-based test provides early risk assessment for spontaneous preterm birth in asymptomatic, singleton pregnancies.
November 29, 2022
Sera Prognostics, Sonrava Health, Cerebrae partner on preterm birth risk
The companies are teaming up to provide Sera's PreTRM Test to members of Sonrava Health's employer-sponsored health insurance program.
October 4, 2022
Sera Prognostics inks deal with MultiPlan for pregnancy test
January 31, 2022
AACC advises against lab testing for premature birth
Preterm delivery is an ongoing problem that can lead to numerous complications for both infants who survive birth and their mothers, according to AACC. To address the issue, medical providers have turned to clinical lab tests that measure fetal fibronectin (fFN), interleukin 6, and placental alpha microglobulin-1 (PAMG-1) that may predict whether a woman will deliver preterm.
June 2, 2021
Sera validates blood test in pregnant women at risk of bad outcomes
The PreTRM test can predict the risk of preterm birth in asymptomatic, singleton pregnancies to help identify infants more likely to be born before 32 weeks of gestation as well as those more likely to experience an increased length of neonatal hospital stay and severe adverse neonatal outcomes, the company noted.
May 21, 2020
USPSTF: Pregnant women may not need vaginosis screening
The recommendation updates the task force's 2008 guideline with a further literature review but is not different, wrote a team led by USPSTF chair Dr. Douglas Owens of Stanford University. The group found that bacterial vaginosis screening just doesn't seem to offer an advantage for avoiding preterm delivery, which has been associated with the condition.
April 7, 2020
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Cheap vaginal-fluid testing signals risk for premature birth
The study involved noninvasive testing of 340 women in midtrimester pregnancy, with the goal of identifying two important signs of risk for preterm birth: depletion of Lactobacillus bacteria in the vaginal microbiome and short cervical length, defined as 25 mm. It was funded by grants from the Bill & Melinda Gates Foundation, the Brazilian Ministry of Health, and the Brazilian National Research Council.
October 21, 2019
Can cheap test prevent newborn deaths? | Amino acid desmosine as biomarker in aneurysms | Brouhaha over DTC genetic tests
Dear LabPulse Member,
October 21, 2019
NIH study finds vaginal bacteria could predict preterm births
A research group led by Jennifer Fettweis, PhD, of Virginia Commonwealth University analyzed data from a subpopulation of over 1,500 women who participated in the NIH Common Fund's Human Microbiome Project. The researchers collected samples of vaginal bacteria from 45 pregnant women who delivered their babies preterm and compared them with samples from 90 women who delivered at full term. Almost 80% of the 135 women were African American.
May 29, 2019
Blood test focuses on PlGF to diagnose pre-eclampsia
Pre-eclampsia often begins after 20 weeks of pregnancy and occurs with the onset of high blood pressure and elevated protein levels in the urine. More severe disease can lead to worsened liver function, damage to other vital organs, and even seizures. Globally, some 100 women die of pre-eclampsia per day.
April 1, 2019
Page 1 of 1